nach oben

Erschienen in:

01.01.2024 | Clinical study

Differences in rates of AESIs between COVID-19 vaccine types

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Rates of some adverse events of special interest (AESIs) differ between mRNA COVID-19 vaccines (Pfizer-BioNTech vaccine [BNT162b2] and Moderna vaccine [mRNA-1273]) and an adenoviral vector COVID-19 vaccine (AstraZeneca vaccine [ChAdOx1]), according to findings of a study published in Clinical Microbiology and Infection . …

Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach Clinical Microbiology and Infection : 13 Dec 2023. Available from: URL: https://doi.org/10.1016/j.cmi.2023.12.010

Titel: Differences in rates of AESIs between COVID-19 vaccine types
Publikationsdatum: 01.01.2024
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-52366-8

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Differences in rates of AESIs between COVID-19 vaccine types

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Vedolizumab

Non-serious case reports

Multiple drugs

Codeine/diphenhydramine

Azithromycin/Methotrexate/Mercaptopurine

Antirheumatics/vedolizumab